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Abstract Toxoplasmosis is one of the most common
parasitic infections in humans, but in most cases it does
not cause serious illness; this protozoan can nevertheless
cause devastating disease in immunocompromised hosts
such as HIV-positive individuals. Only rarely is toxoplas-
mosis documented in hematological patients, and among
them, those who undergo a transplant procedure are more
frequently affected. In a retrospective multicenter survey,
we collected data on six cases of toxoplasmosis in
hematological patients. In the majority of cases, patients
had undergone transplant procedures (five had undergone
autologous or allogeneic transplantation). This complica-
tion needed special care in diagnosis, usually based on
serology, neuroradiology, and PCR examination. Howev-
er, in our experience the appropriate therapeutic approach
was successful in the majority of cases.
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Introduction
Toxoplasmosis is a rare but often lethal complication in the
immunocompromised host such as AIDS patients or bone
marrow transplant (BMT) recipients, so that most of the
published reports about this topic refer to these two
categories of patients; its rates have risen since the
outbreak of HIV and the more widespread use of BMT
procedures in the management of hematological malig-
nancies [1–4].
In immunocompetent individuals, acute toxoplasmosis
most often results in asymptomatic infection [5]. In the
immunocompromised patient, conversely, toxoplasmosis
may cause fulminant disseminated disease, localized in
most cases in the central nervous system (CNS).
In a review of current literature, approximately 112
cases of disseminated toxoplasmosis following BMT were
reported [3]. In most of the cases, the diagnosis was made
only at autopsy; brain, lungs, and heart were the most
frequently involved organs.
In the present study we want to analyze the clinical
characteristics of Toxoplasma gondii infection and the
procedures that favored diagnosis of, and a better outcome
for, patients affected by hematological malignancies
admitted during a 10-year period in GIMEMA (Gruppo
Italiano Malattie Ematologiche dell’Adulto) centers.
Materials and methods
All cases of toxoplasmosis in adult patients (>12 years of age) with
hematological malignancies, observed between January 1993 and
December 2002 in 21 GIMEMA centers, were retrospectively
collected. Hospital records of patients with toxoplasmosis were
reviewed to gather information regarding demographic data (age,
sex), and type and stage of underlying hematological disease;
patients with a hematological malignancy related to HIV infection
were excluded from the study, because of the high incidence of
toxoplasmosis in AIDS patients.
Further, the date of diagnosis of each new case, clinical
manifestations at presentation, radiological imaging, and antigen
detection in serum were reviewed. Data on type of drugs employed
and total doses and duration of treatment for toxoplasmosis were
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also noted. Patients had a follow-up of 100 days after the diagnosis
of toxoplasmosis. Mortality was judged to be due to toxoplasmosis
when death occurred within 30 days of the diagnosis. An autopsy
was carried out on all patients who died.
In clinical practice, diagnosis of toxoplasmosis, particularly of
CNS localization, is based on noninvasive methods:
(a) Serology and polymerase chain reaction (PCR)
(b) Response to antitoxoplasmosis therapy: clinical improvements
are generally observed after 2 or 3 weeks of treatment
(c) Radiological pattern, in particular nuclear magnetic resonance
(NMR), with characteristic features, such as multiple ring-
enhancing lesions, with edematous reaction and mass effect
When the clinical or radiological evidence is not conclusive, a
brain biopsy should be considered as soon as possible [6].
Results
During the study period, a total of six toxoplasmosis cases
were observed in five hematological centers. In the
remaining 16 centers, no toxoplasmosis cases occurred.
The hematological diagnosis was Hodgkin’s disease (HD)
and acute lymphoblastic leukemia (ALL) in two cases
each, and non-Hodgkin’s lymphoma (NHL) and acute
myeloid leukemia (AML) in one case each. Apart from the
case with AML, all patients had undergone a transplant
procedure before developing toxoplasmosis.
Except for one patient who presented toxoplasmosis at
diagnosis of AML, four patients were in remission of the
malignancy, after autologous transplantation (autoBMT)
or allogeneic transplantation (alloBMT), at the time of
diagnosis of the complication, while the other one
presented a relapse after alloBMT. The allogeneic trans-
plant recipients presented graft-versus-host disease
(GVHD) when toxoplasmosis occurred (Table 1).
In the absence of documented cases of toxoplasmosis
from 16 centers participating to the survey, the incidence
of toxoplasmosis was evaluated only in the centers that
reported a proven or suspected case; furthermore, this
evaluation was conducted only on transplant patients, who
represented the majority of cases. During the study period,
in the five centers that observed cases of toxoplasmosis,
2,574 transplant procedures were performed: 2,193 pa-
tients underwent an autologous transplantation, the
remaining 381 patients were treated with an allogeneic
transplantation. Thus, the global incidence of toxoplas-
mosis was 1.9/1,000 patients, while the incidence relative
to autologous or allogeneic transplantation was 0.9/1,000
patients and 8/1,000 patients, respectively. General
features of patients are shown in Table 1; the proportion
of males to females was 4:2; ages ranged between 18 years
and 66 years.
Four patients received steroid treatment: in three cases,
steroids were still administered at the time of diagnosis of
infection; these patients received steroid therapy for a
median period of 35 days (30–150), with a median daily
dosage of 37.5 mg of methyl-prednisolone (range 15–60)
and a median total dose of 1,800 mg (range 900–2,100).
Five patients presented a low absolute neutrophil count
at the time of diagnosis of toxoplasmosis, with a median
level of 0.9×109 l−1 (range 0.45–1.2×109 l−1); in four of
these cases, lymphocyte count also was lower than normal,
with a median level of 0.45×109 l−1, ranging between 0.2
and 0.6.
Prophylactic approaches differ according to each
participating center and according to the personal clinical
experience. Only one patient had received a prophylactic
treatment with pentamidine, while in the other five cases,
no prophylaxis was administered.
Table 2 shows the clinical presentation of toxoplasmosis
in these patients. In five cases, CNS was involved, as the
only localization or as one of the sites of infection. The
most frequent signs in these patients were neurological
disorders, such as seizure, cephalalgia, and projectile
vomiting: the only case who did not show such a
symptomatology presented a blood-limited infection.
Fever was present in four patients: in three patients with
CNS involvement, and in the patient with blood-limited
infection; two patients with CNS involvement did not
show fever. None of these patients suffered for pneumonia.
In four cases, a brain magnetic nuclear resonance
(MNR) was performed, revealing multiple bilateral
hypodense or hyperdense subcortical areas; in another
patient a brain computed tomography (CT) scan was
positive for “multiple hypodense lesions” with a moderate
contrast enhancement.
In all cases, the test for serological positivity for anti–T.
gondii IgM/IgG was performed; in two of these patients
serological examinations performed before the transplant
procedure had shown an IgG positivity.
During infection, IgM positivity was found in only two
cases. In one of these patients, T. gondii was also detected
in the spinal fluid by microbiological examination. The
other patient presented a concomitant Cryptococcus neo-
formans infection. As a rule, all hematological patients are
screened for Toxoplasma infection, and the rate of IgG
positivity is about 50%, as in the general population.
In the only patient who underwent a CNS biopsy, a PCR
analysis was conducted on cerebral tissue, showing the
presence of the parasite’s DNA. The immunohistochem-
ical assay conducted at the same time gave a negative
result. Only in one case did the infection remain
undiagnosed until death; in this case, time of onset of
the complication remained unknown; in one case, toxo-
Table 1 General features of patients with toxoplasmosis. HD
Hodgkin’s disease, N-S nodular sclerosis, ALL acute lymphoblastic
leukemia, AML acute myeloid leukemia, NHL non-Hodgkin’s
lymphoma, autoPBSCT autologous peripheral blood stem cell
transplantation, alloBMT allogeneic bone marrow transplantation,
PR partial remission, CR complete remission, Na not applicable.
Patient Sex Age Pathology BMT GVHD Status
1 M 46 HD N-S IIIB autoPBSCT Na PR
2 M 18 ALL MUD Yes CR
3 M 22 HD AlloBMT Yes CR
4 M 54 AML No Na Onset
5 F 29 ALL AlloBMT Yes Relapse
6 F 66 NHL autoPBSCT Na CR
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plasmosis was diagnosed at the onset of the hematological
malignancy, while in the other cases the detection of T.
gondii occurred between 40 and 120 days after the last
chemotherapy. Three patients were empirically treated
with high dose broad-spectrum antibiotics at the onset of
fever; the other patients did not receive any empirical
treatment.
Once the diagnosis was at least presumptively achieved
in five patients, they were specifically treated with
pyrimethamine and sulfadiazine, or spiramycin. The
patient who remained undiagnosed and presented a
disseminated infection did not receive any antimicrobial
treatment and died. All the remaining five patients showed
good improvement in their CNS lesions.
All patients were alive at day 30 from the diagnosis of
infection, or from the probable onset of infection in the
undiagnosed case. After 6 months from diagnosis, two of
them were still alive, three had died because of the basic
pathology; only in one case did toxoplasmosis account for
death; an autopsy was carried out only in one case.
Discussion
This study, conducted on the basis of a retrospective
multicenter survey, clarifies the relevance of toxoplasmo-
sis in the managing of oncohematological malignancy
patients. Our data demonstrate that toxoplasmosis is quite
negligible in those patients with hematological malignan-
cies who do not undergo transplant procedures, in fact we
observed only one case of toxoplasmosis in this kind of
patient. Furthermore, while toxoplasmosis is very rare
during autologous procedures (less than 1/1,000), its
incidence seems to be appreciable in allogeneic transplan-
tation (8/1,000): these findings confirm previously re-
ported data [7]. In consideration of the fact that in the
majority of centers no cases were registered we must
consider that the incidence there is lower than that in
centers that reported cases.
This series allows us to confirm the importance of
heavy immunosuppression in the development of this
complication. In fact all alloBMT recipients suffered from
a GVHD at the time of infection, and three patients
presented a low lymphocyte count, as happens in AIDS
patients: these data are consistent with the widespread
occurrence of toxoplasmosis among HIV patients [8].
Toxoplasma gondii encephalitis is the main clinical
presentation and can be difficult to confirm by serological
test; usually the clinical diagnosis is supported by
demonstration of brain lesions on CT scan or, better,
NMR [9]. The radiological findings often show typical
multiple lesions in the basal ganglia and in the
corticomedullary junction of the cerebral and cerebellar
hemispheres.
In our series, diagnosis remained presumptive in three
out of six patients until the response to antimicrobial
therapy [10]; in the other cases, diagnosis was achieved by
cultural examination of liquor [11], by PCR testing of a
cerebral lesion [12], and by autopsy.
Only in one case could the infection be reasonably
associated with death, based on its resistance to antimi-
crobial therapy, but even this patient was still alive at day
30 from diagnosis. In contrast to the 66% mortality rate in
bone marrow recipients that has been reported in the
literature, we observed a mortality rate of 20% among our
BMT recipients with toxoplasmosis [3, 8].
In conclusion, it is possible that diagnostic problems
lead to an underestimation of the real incidence of this
infectious complication [13]: a diagnostic approach is still
not standardized in GIMEMA centers; usually it should
consist of serological, radiological, histopathological
(when possible), and PCR-based techniques [14]. On the
other hand, the rarity of toxoplasmosis in this setting could
be associated with the widespread use of trimethoprim/
Table 2 Clinical presentation of Toxoplasma infection. C communitarian, N nosocomial, CNS central nervous system, MNR magnetic
nuclear resonance, PCR polymerase chain reaction
Patient Source Symptoms Site of
infection
Absolute neutrophil count (per
mm3)
Empirical
treatment
Radiological
findings
Diagnosis
1 C Fever, fatigue, cepha-
lalgia
CNS 600 Yes Brain MNR:
multiple le-
sions
PCR on CNS biopsy
2 C Fever, projectile
vomiting
CNS 1,100 Yes Brain CT:
multiple le-
sions
Presumptive
3 C Fever, left side paresis CNS 1,200 Yes Brain MNR:
two lesions
Presumptive
4 C Fever Blood 450 No None Presumptive
5 N Fever, cephalalgia
projectile vomiting
Disseminated 900 No Brain MNR:
multiple le-
sions
Autopsy
6 C Fatigue CNS 3,000 No Brain MNR:
multiple le-
sions
Serology, lumbar
puncture
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sulfametoxazole (or pentamidine)–based prophylaxis [7]:
in our series, five out of six patients who developed
toxoplasmosis had not received any prophylactic treat-
ment.
The absence of observations of toxoplasmosis at
autopsy in the patients who died in the participating
centers in this study, induces us to retain our view that
toxoplasmosis represents an infectious complication that is
rarely of concern in hematological malignancies.
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